Form 4: Palisade Bio Director Granted 64,400 Phantom Units

Palisade Bio, Inc. director Donald Allen Williams was granted 64,400 phantom units, which vest over three years and are cash-settled.

Summary

• Donald Allen Williams, a director of Palisade Bio, Inc. (PALI), was granted 64,400 phantom units on September 4, 2025.
• Each phantom unit is the economic equivalent of one share of the Issuer's common stock.
• The phantom units will vest in three equal annual installments, with the first installment commencing on August 5, 2026.
• Vesting is contingent upon Mr. Williams' continuous service through each applicable vesting date.
• Vested phantom units will be settled solely in cash, based on the fair market value of an equal number of common stock shares.
• Settlement will occur on the earliest of Mr. Williams' termination of continuous service, a Liquidity Change in Control (as defined in the Phantom Unit Plan), or the 7th anniversary of the grant date.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The grant of phantom units is a routine compensation event for a director, indicating continued engagement and alignment of interests, but does not reflect new operational or financial performance.

Positives

• The grant of phantom units aligns the director's interests with shareholder value, as the units' value is tied to common stock performance.
• The multi-year vesting schedule encourages long-term commitment and continuous service from a key director, fostering stability in leadership.

Negatives

• There is no immediate cash inflow for the director, as the units are cash-settled only upon vesting and the occurrence of specific future events.
• The value realized by the director is entirely dependent on the future fair market value of Palisade Bio's common stock, introducing market risk.

Risks

• The value of the phantom units is subject to the future fair market value of Palisade Bio's common stock, which can fluctuate significantly.
• Vesting is conditional on continuous service, meaning the director could forfeit unvested units if their service terminates prematurely.
• The definition of 'Liquidity Change in Control' and its impact on settlement could introduce complexity and potential for differing interpretations.

Future Outlook

The grant of phantom units with a multi-year vesting schedule suggests an expectation of continued service from the director and a long-term focus on company performance and shareholder value creation.

Industry Context

Equity grants, including phantom units, are a common form of executive and director compensation in the biotechnology and pharmaceutical industries. This practice aims to align leadership incentives with long-term shareholder value creation and retain key talent in a competitive sector.

Comparison to Industry Standards

• The grant of phantom units is a standard practice for director compensation in many public companies, particularly in the biotech sector, to incentivize long-term performance and retention.
• The three-year vesting schedule is typical for equity awards, providing a balance between immediate reward and long-term commitment, comparable to similar grants observed across the industry.
• Cash settlement upon specific events is also a common feature for phantom units, differentiating them from stock options or restricted stock units that settle in shares, and is consistent with compensation structures designed to manage dilution while providing equity-linked incentives.

Stakeholder Impact

• Shareholders: The grant aligns the director's long-term financial interests with the company's stock performance, potentially benefiting shareholder value.
• Management: Reinforces the compensation structure for key leadership, promoting retention and performance incentives.

Next Steps

• Continued service of Donald Allen Williams as a director of Palisade Bio, Inc.
• Vesting of the 64,400 phantom units in three equal annual installments, commencing August 5, 2026.
• Future cash settlement of vested phantom units upon the earliest occurrence of specified events (service termination, Liquidity Change in Control, or 7th anniversary of grant date).

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a director as part of their compensation package. It does not contain information about the company's operational performance, financial results, or strategic shifts that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining the current stance until further substantive news is released.

Keywords

Palisade Bio, PALI, Form 4, Phantom Units, Equity Grant, Director Compensation, Executive Compensation, Vesting, SEC Filing